Improving gout treatment with engineered uricase
Advanced Uricase Engineering for Improved Outcomes in Gout Patients
This study is working on a new version of an enzyme that helps lower uric acid levels, aiming to create a safer and more effective treatment for people with gout who haven't found relief with other options.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cyrus Biotechnology, INC. NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11008432 on NIH RePORTER |
What this research studies
This research focuses on developing a new form of uricase, an enzyme that helps break down uric acid, to improve treatment outcomes for patients suffering from gout. By engineering variants of uricase that are more stable and less likely to trigger immune reactions, the research aims to create a safer and more effective therapeutic option. The approach involves screening different uricases from various organisms and using advanced computational modeling to enhance their properties. Patients with chronic refractory gout may benefit from this innovative treatment that aims to reduce adverse effects associated with current therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who suffer from chronic refractory gout and have not responded well to existing treatments.
Not a fit: Patients with mild gout or those who have not been diagnosed with chronic refractory gout may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide gout patients with a more effective and safer treatment option, reducing the frequency and severity of gout attacks.
How similar studies have performed: Other research has shown promise in engineering enzymes for therapeutic use, indicating that this approach could lead to significant advancements in gout treatment.
Where this research is happening
Seattle, United States
- Cyrus Biotechnology, INC. — Seattle, United States (Active)
Researchers
- Principal investigator: Chan, Kui Kiu — Cyrus Biotechnology, INC.
- Study coordinator: Chan, Kui Kiu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.